Last reviewed · How we verify
Pravastatin, Carvedilol, Perindopril
Pravastatin, Carvedilol, Perindopril is a Small molecule drug developed by University Hospital, Strasbourg, France. It is currently FDA-approved.
At a glance
| Generic name | Pravastatin, Carvedilol, Perindopril |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pravastatin, Carvedilol, Perindopril CI brief — competitive landscape report
- Pravastatin, Carvedilol, Perindopril updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI
Frequently asked questions about Pravastatin, Carvedilol, Perindopril
What is Pravastatin, Carvedilol, Perindopril?
Pravastatin, Carvedilol, Perindopril is a Small molecule drug developed by University Hospital, Strasbourg, France.
Who makes Pravastatin, Carvedilol, Perindopril?
Pravastatin, Carvedilol, Perindopril is developed and marketed by University Hospital, Strasbourg, France (see full University Hospital, Strasbourg, France pipeline at /company/university-hospital-strasbourg-france).
What development phase is Pravastatin, Carvedilol, Perindopril in?
Pravastatin, Carvedilol, Perindopril is FDA-approved (marketed).